Preclinical imaging of therapy response using metabolic and apoptosis molecular imaging

M. de Saint Hubert, H. Wang, E. Devos, K. Vunckx, L. Zhou, C.P. Reutelingsperger, A. Verbruggen, L. Mortelmans, Y. Ni, F.M. Mottaghy

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

PURPOSE: Early after therapy, 2-deoxy-2-[(18)F]fluoro-D-glucose ([(18)F]FDG) imaging is not always reliable due to the influx of inflammatory cells while apoptosis imaging offers a direct and early measurement of therapy effects. This study uses an improved apoptosis probe ((99m)Tc-hAnxA5) in combination with [(18)F]FDG imaging to evaluate therapy response. PROCEDURES: Daudi tumor tissue was implanted in the spleen of SCID mice. Treatment was performed with adriamycin and cyclophosphamide. Sequential [(18)F]FDG-positron emission tomography (PET) was acquired over 6 days and (99m)Tc-hAnxA5-SPECT was performed before and 1 day after therapy. RESULTS: On day 1, therapy induced apoptosis was visualized with (99m)Tc-hAnxA5 without a measurable change in [(18)F]FDG uptake. [(18)F]FDG uptake decreased significantly on day 3 and was even more pronounced on day 6. CONCLUSION: In this preclinical model, (99m)Tc-hAnxA5 imaging was able to detect apoptosis before metabolic changes were measured. These results confirm the value of apoptosis imaging for therapy response and give more insight in [(18)F]FDG imaging and its parameters to evaluate response.
Original languageEnglish
Pages (from-to)995-1002
Number of pages8
JournalMolecular Imaging and Biology
Volume13
Issue number5
DOIs
Publication statusPublished - Oct 2011

Keywords

  • Lymphoma
  • Chemotherapy response
  • MRI
  • [(18)F]FDG and (99m)Tc-hAnxA5
  • NON-HODGKINS-LYMPHOMA
  • POSITRON-EMISSION-TOMOGRAPHY
  • ANNEXIN-V
  • CELL-DEATH
  • TUMOR RESPONSE
  • CANCER-THERAPY
  • IN-VIVO
  • CHEMOTHERAPY
  • RADIOTHERAPY
  • DAUDI

Cite this